Trial Profile
Variation of choroidal Thickness 15 days after the first ranibizumab intravitreal injection in naive patients WIth Neovascular age-related macular degeneration: pilot Study. –
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 May 2016
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 17 May 2016 Status changed from recruiting to completed, as per results published in the BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.
- 17 May 2016 Primary endpoint has not been met. (Variation of choroidal thickness from baseline visit (first ranibizumab injection) to day 15.), as per results published in the BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.
- 17 May 2016 Results published in the BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy